济南生殖的检查济南治疗生殖感染大概要多少钱,济南早泄用什么中药治疗,济南治疗早射多长时间恢复,济南外科是看什么的,济南鬼头发炎是什么症状,济南前列腺炎不治会怎样,济南小腹睾丸疼痛

BEIJING, Dec. 18 (Xinhua) -- China's economic diplomacy will face growing challenges in the form of trade and exchange rate disputes, as well as the task of protecting overseas investment interests, over the next few years, experts said on Sunday.Next year will be an election year for the Unite States and France, and there is an increasing possibility for the two countries to use the "China threat" as an excuse for not dealing with their own economic issues, which will put Chinese diplomacy under pressure, said Ding Yifan, deputy director of the Institute of World Development of the Development Research Center of the State Council at a seminar on Chinese diplomacy.During the first half of 2012, several countries will remain in a grave debt crisis and may even see their crises deepen, Ding said, adding that this situation may create friction between China, the United States and Europe.Additionally, protecting China's growing overseas investments will pose new challenges for the country's diplomacy, Ding said.Chen Fengying, director of the Institute of World Economic Studies under the China Institutes of Contemporary International Relations, agreed that the protection of China's overseas investment interests will be an important task for Chinese diplomacy.During the past three decades, China has invested in more than 170 countries and regions, with outbound direct foreign investment topping 170 billion U.S. dollars.In the past 30 years, China has been focused on "bringing in" foreign investment; it may do more to facilitate its "going out" in the future, Chen said.Chinese economic diplomacy will serve the country's economic construction and the protection of its overseas interests, national interests and security, Chen said, adding that China's position in the world is closely related to its economic diplomacy.Chen said China has made several achievements in international economic governance, reflected by China's growing influence in the international arena and the posts held by Chinese officials in important international organizations.

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.

OTTAWA, Oct. 3 (Xinhua) -- Many friends and colleagues of Canadian scientist Ralph Steinman reacted with shock when they learned on Monday that Steinman won the Nobel Prize for Medicine and Physiology three days after he died.Since 1974, Nobel Prizes are no longer awarded posthumously, but the Nobel Prize committee said that it had made its choice before Steinman's death.Many of Steinman's friends and colleagues said that they learned of Steinman's death at the same time that they learned of his Nobel Prize, which was awarded for a discovery Steinman made in 1973.Steinman, 68, discovered dendritic cells, which help regulate adaptive immunity, which purges invading microorganisms from the body. Dendritic cells activate T cells, which "remember" the DNA sequence of invading organisms and protect the body from later infections from the same disease."Their work has opened up new avenues for the development of prevention and therapy against infections, cancer and inflammatory disease," the citation said.Monday, the Nobel Committee defended its decision to award the prize to Steinman. "The decision to award the Nobel Prize to Ralph Steinman was made in good faith, based on the assumption that the Nobel Laureate was alive," the foundation said in a statement."The Nobel Foundation thus believes that what has occurred is more reminiscent of the example in the statutes concerning a person who has been named as a Nobel Laureate and has died before the actual Nobel Prize Award Ceremony."It is still unclear who will pick up Steinman's prize at the award ceremony later this year.Steinman, a cell biologist at Rockefeller University in New York City, died of pancreatic cancer on Friday. For more than four years, he had used his own immune therapy discoveries to extend his life."The news is bittersweet, as we also learned this morning from Ralph's family that he passed a few days ago," Rockefeller University President Marc Tessier-Lavigne said in a statement."We are all so touched that our father's many years of hard work are being recognized with a Nobel Prize," Steinman's daughter, Alexis, said in the statement. "He devoted his life to his work and his family, and he would be truly honored."Steinman's heirs will share the 1.5-million U.S. dollar prize with American genetics professor Bruce Beutler and French scientist Jules Hoffmann.Dr. Beutler is professor of genetics and immunology at The Scripps Research Institute in La Jolla, California. Dr. Hoffmann headed a research laboratory in Strasbourg, France, between 1974 and 2009 and served as president of the French National Academy of Sciences between 2007 and 2008."Ralph worked right up until last week," said Michel Nussenzweig, a collaborator of Steinman's at Rockefeller University. "His dream was to use his discovery to cure cancer and infectious diseases like HIV and tuberculosis. It's a dream that's pretty close."Steinman was born in 1943 in Montreal, Canada's second largest city, and studied chemistry and biology at McGill University in his hometown before receiving an MD from Harvard Medical School in Boston in 1968. He joined Rockefeller University in 1970 as a postdoctoral fellow."He was diagnosed with pancreatic cancer four years ago, and his life was extended using a dendritic-cell based immunotherapy of his own design," the university said in a statement.In a statement, Canadian Prime Minister Stephen Harper lauded the three winners of the Nobel for medicine and called the award " a fitting final tribute" to Steinman's life's work."Dr. Steinman shall be honored for all time with this achievement," Harper said. "Canadians will mourn his loss."

HANOI, Oct. 25 (Xinhua) -- The hand-foot-mouth disease (HFMD) and dengue were on the rise across Vietnam, reported the Vietnam Preventive Medicine Administration (PMA) on Tuesday.As of Oct. 23, the country had more than 76,120 HFMD patients and 135 fatalities. The number of incidents has increased significantly over the last few weeks, with an average of 2,000-2, 500 new cases reported each week.Southern Ho Chi Minh City and Binh Duong, Long An and Quang Ngai were the most-hit localities, said the report.Meanwhile, dengue was also reported on the rise. In the first ten months of the year, there were more than 41,200 infected cases and 32 fatalities. Currently, an average of 2-3 cases a day were hospitalized by dengue infections, mainly from capital Hanoi.Epidemiologists said that the increase of HFMD and dengue was due to the lack of specialized medicine and preventive vaccines. In addition, complicated climate change, environment pollution and low awareness of the disease among the community have contributed to the spread of the diseases nationwide.

SAN FRANCISCO, Nov. 28 (Xinhua) -- Amazon.com on Monday announced that this past Black Friday was the best ever for its Kindle products with consumers buying four times as many Kindle e- readers and tablets as they did last year.According to the online retail giant, its newly launched tablet Kindle Fire was the bestselling product across all of Amazon.com on Black Friday, the day after Thanksgiving, which falls on Nov. 25 this year, when major retailers in the United States traditionally offer big discounts.Kindle Fire is Amazon's answer to Apple's popular iPad. Priced at 199 U.S. dollars, the Amazon product is much cheaper than iPad which starts from 499 dollars.Survey results by research firm ChangeWave Research released days before Black Friday indicated that Amazon is poised to become the No. 2 player in the tablet computer market behind Apple, due to strong demand for Kindle Fire.Amazon said Black Friday sales also showed that a lot of customers were buying multiple Kindles, one for themselves and others as gifts.The trend is expected to continue through this holiday shopping season, Amazon's vice president of Kindle products Dave Limp said in a statement.